



JCO2 Recd PCT/PTO 07 MAY 2002

Attorney Docket No. 463456,776

RECEIVED
JUN 03 2002
TECH CENTER 1600 OF PAPERS
CORRESPONDENCE
ORIGINALLY FILED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): H. Kimura, et al.

EXAMINER: Unassigned

SERIAL NO.: 10/009,693

GROUP: 1614

FILED: December 10, 2001

FOR: NOVEL PROTEIN AND DNA THEREOF

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on April 25, 2002.

By: 

Donna M. Tomaso

ASSISTANT COMMISSIONER OF PATENTS
WASHINGTON, DC 20231

Sir:

REQUEST FOR CORRECTED FILING RECEIPT

Applicants respectfully request the correction of the Filing Receipt for the following mistake:

- 1) In the Title, please change as follows:

Novel Protein and DNA Thereof

A copy of the Filing Receipt with the changes marked in Red is enclosed for your convenience.

Since the correction is not due to any error by applicant, there is no fee due.

The Commissioner is hereby authorized to charge any fees which may be required to Deposit Account No. **04-1105**.

Respectfully submitted,

Date: April 25, 2002


By: 

Cara Z. Lowen
Reg. No. 38,227
Attorney for Applicant(s)

Dike, Bronstein, Roberts & Cushman
Intellectual Property Practice Group
EDWARDS & ANGELL, LLP
P.O. Box 9169
Boston, Massachusetts 02209
(617) 517-5509
Customer No. 21874
298932



UNITED STATES PATENT AND TRADEMARK OFFICE



RECEIVED

JUN 05 2002


TECH CENTER 1600/2900

WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
10/009,693	12/10/2001	1614	1606	46342 /56776	2	19	1

CONFIRMATION NO. 1297

David G Conlin
Dike Bronstein Roberts & Cushman
130 Water Street
Boston, MA 02209



FILING RECEIPT



OC000000007555556

Date Mailed: 03/01/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Hiroyuki Kimura, Osaka, JAPAN;
Junichi Sakamoto, Osaka, JAPAN;
Hidekazu Sawada, Osaka, JAPAN;

COPY OF PAPERS
ORIGINALLY FILED

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A 371 OF PCT/JP00/03720 06/08/2000

Foreign Applications

JAPAN 163924/1999 06/10/1999

Projected Publication Date: Not Applicable, filed prior to November 29, 2000

Non-Publication Request: No

Early Publication Request: No

Title

DNA
Novel protein and ~~one~~ thereof

Preliminary Class

514

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).